Start of new trial of LB54640, an oral MC4R agonist, in patients with hypothalamic obesity due to acquired hypothalamic injury
Start of new trial of Tirzepatide in adolescent patients with obesity and weight-related comorbidities.
Within a given environment, some people put on weight very easily, whilst others remain thin. We aim to understand the key mechanisms that control body weight to inform the development of safe, effective weight loss interventions. We use genetic, molecular and clinical approaches to study cohorts of individuals with severe obesity and thinness.
Latest News See all news>>
Start of new trial of LB54640, an oral MC4R agonist, in patients with hypothalamic obesity due to acquired hypothalamic injury
We would like to thank colleagues who refer patients to GOOS, research collaborators, funding bodies, former members of the GOOS team and the patients, families and volunteers who support our research.
Contact Us
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
University of Cambridge Metabolic Research Laboratories
Level 4, Institute of Metabolic Science
Box 289, Addenbrooke's Hospital
Cambridge, CB2 0QQ
